The Science & Treatment of Bipolar Disorder

Summary

Bipolar disorder is a serious psychiatric condition affecting approximately 1% of the population, characterized by extreme shifts in mood, energy, and perception. This episode covers the biology of bipolar disorder, its two main clinical subtypes, the landmark discovery of lithium as a treatment, and the neural circuit mechanisms underlying the condition. The discussion also distinguishes bipolar disorder from major depression and borderline personality disorder.

---

Key Takeaways

• Bipolar disorder carries a 20–30 times greater risk of suicide than the general population, making early recognition critically important.
• Bipolar 1 is defined by manic episodes lasting 7 days or more; Bipolar 2 involves hypomanic episodes of 4 days or fewer, often paired with major depressive episodes.
• People with bipolar disorder spend significant time symptom-free — roughly 53% (Bipolar 1) and 45% (Bipolar 2) — making diagnosis especially challenging.
• Heritability of bipolar disorder is approximately 85%, far higher than major depression (20–45% concordance in identical twins), suggesting a strong genetic susceptibility.
• Lithium, discovered serendipitously in 1949, remains a frontline treatment but requires careful blood monitoring due to toxicity risks.
• Bipolar disorder involves a progressive atrophy of interoceptive neural circuits, impairing the person’s ability to sense their own emotional and physical states.
• Borderline personality disorder can resemble bipolar disorder but is distinguished by the presence of an external trigger for mood episodes, whereas bipolar episodes can arise without any trigger.
• Bipolar 2 is often misidentified as major depression because hypomanic episodes are brief (~4–5% of the person’s time) and depressive episodes dominate (~50% of the time).

---

Detailed Notes

Defining Bipolar Disorder

• Bipolar disorder (also called bipolar depression) involves maladaptive shifts in mood, energy, and perception.
• Affects ~1% of the global population; onset typically between ages 20–25, though earlier onset predicts a more persistent course.
• Earlier onset = higher likelihood the disorder becomes a stable feature of the person’s psychology.

---

Bipolar 1 vs. Bipolar 2

Bipolar 1

• Defined by manic episodes lasting 7 or more consecutive days.

• Requires at least 3 of 7 symptom categories to be present:

  1. Distractibility — rapid shifting of attention to any stimulus
  2. Impulsivity — excessive, uncharacteristic purchases or actions (e.g., buying 10+ air fryers, booking multiple international trips)
  3. Grandiosity — delusional beliefs about one’s special status or abilities (e.g., believing they will win a Pulitzer Prize that afternoon)
  4. Flight of ideas — rapid jumping between unrelated topics without logical transitions
  5. Agitation — extreme physical restlessness and inability to be still; can involve paranoia
  6. Decreased need for sleep — some individuals go 7+ days with zero sleep and are unbothered by it
  7. Rapid pressured speech — machine-gun-like delivery with no space for dialogue

• Mania must not be better explained by TBI, seizures, illicit drugs (e.g., cocaine, amphetamines), or corticosteroids.

• Does not always include depressive episodes — many bipolar 1 patients return to baseline rather than dropping into depression.

Bipolar 2

• Characterized by hypomanic episodes (shorter or less intense mania, ~4 days or fewer) plus major depressive episodes.
• People with Bipolar 2 spend approximately:
  • ~50% of time depressed
  • ~45% symptom-free
  • ~4–5% in hypomanic states
• Because hypomanic phases are brief and depressive phases dominate, Bipolar 2 is frequently misdiagnosed as major depression.
• Self-medication with alcohol or isolation during depressive phases can further obscure the diagnosis.

Time Spent in Each State (from Judd et al., JAMA Psychiatry)

State	Bipolar 1	Bipolar 2
Symptom-free	~53%	~45%
Depressed	~32%	~50%
Manic/Hypomanic	~15%	~4–5%

---

Genetics and Heritability

• General population prevalence: 1% bipolar disorder, 10–17% major depression.
• Identical twin concordance:
  • Major depression: 20–45%
  • Bipolar disorder: 40–70%
• Overall heritability of bipolar disorder: ~85% — one of the highest of any psychiatric condition.
• No single identified gene; rather, a genetic susceptibility that interacts with environmental factors (e.g., early life stress, trauma).
• Having a first-degree relative (parent, sibling, twin) with bipolar disorder significantly elevates personal risk.

---

Bipolar Disorder vs. Borderline Personality Disorder

• Key distinction: Bipolar episodes arise spontaneously without an external trigger; borderline personality disorder (BPD) mood shifts are almost always triggered by an environmental event or relationship perception.
• BPD hallmark: Splitting — abruptly shifting someone from “idealized” (can do no wrong) to “devalued” (enemy/threat) status.
• Both conditions involve significant suffering for the individual experiencing them.
• BPD will be covered in a separate dedicated episode.

---

The Discovery of Lithium

• Dr. John Cade, an Australian psychiatrist and WWII prisoner of war, hypothesized that a buildup of a urinary chemical caused mania.
• After the war, he injected guinea pigs with urine from manic vs. non-manic patients and noted the former was more toxic.
• In attempting to dilute uric acid for injection, he used lithium to create lithium urate — and discovered it had a calming effect on guinea pigs.
• Control experiments confirmed lithium alone produced the calming effect.
• He administered lithium to human patients and documented dramatic reductions in manic symptoms.
• Published: “Lithium Salts in the Treatment of Psychotic Excitement”, Medical Journal of Australia, September 3, 1949.
• The FDA did not approve lithium for bipolar disorder in the US until 1970 — 21 years later.
• Lithium was never patented because it is a naturally occurring element (element #3 on the periodic table), limiting pharmaceutical profit incentive.

---

How Lithium Works (Mechanisms)

• Increases BDNF (brain-derived neurotrophic factor): Opens the gates for neuroplasticity — it doesn’t create specific changes but makes neurons more capable of changing in response to environment.
• Anti-inflammatory: Suppresses neural and brain tissue inflammation, which is implicated in the progression of bipolar disorder.
• Neuroprotective: Helps neurons withstand excitotoxicity — a process in which hyperactive circuits release excess calcium and glutamate, killing the very neurons involved.
• Lithium requires ongoing blood level monitoring due to toxicity risk, especially in the first 3 months of treatment.

---

Neural Circuit Basis of Bipolar Disorder

• Two major mechanisms:

  1. Hyperactivity of certain circuits early in the disease — particularly circuits involved in emotional regulation and arousal.
  2. Progressive atrophy of interoceptive circuits — over time, especially in the 2nd and 3rd decades of living with bipolar disorder.

• Interoception — the perception of internal states (heart rate, fullness, mood, energy level) — becomes progressively impaired in people with bipolar disorder.

• Exteroception (perceiving the external world) remains more intact.

• The progressive interoceptive deficit helps explain why individuals in a manic episode often cannot perceive that they haven’t slept in days or are speaking abnormally fast.

• Lithium’s